Pfizer (PFE)
23.87
-0.99 (-3.98%)
NYSE · Last Trade: Sep 13th, 10:45 AM EDT
How does $700 in annual income sound for every $10,000 in shares owned?
Via The Motley Fool · September 13, 2025
The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future..
Via The Motley Fool · September 12, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 7.8% in the afternoon session after reports revealed Trump administration health officials plan to link COVID-19 vaccines to the deaths of around two dozen children.
Via StockStory · September 12, 2025
Shares of global pharmaceutical company Pfizer (NYSE:PFE)
fell 3.5% in the afternoon session after reports revealed federal health officials are planning to link COVID-19 vaccines to the deaths of children.
Via StockStory · September 12, 2025
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Insidestocktwits.com
Via Stocktwits · September 8, 2025
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is fundamentally altering the landscape of medical treatment and diagnostics, promising a future of more personalized, precise, and preventive medicine. At the forefront of this
Via MarketMinute · September 12, 2025
Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths.
Via Benzinga · September 12, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · September 12, 2025
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · September 12, 2025
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
Via StockStory · September 12, 2025
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.
Via Benzinga · September 11, 2025
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via StockStory · September 11, 2025
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.
Via Investor's Business Daily · September 10, 2025
The global economy is once again grappling with the disquieting prospect of stagflation, a rare and challenging economic phenomenon defined by the simultaneous occurrence of slow economic growth, high unemployment, and persistent inflation. This peculiar confluence, which defies traditional economic models, is sending ripples of concern through financial markets and
Via MarketMinute · September 10, 2025
Top health officials under Kennedy are pushing for more transparency on Covid vaccine risks, focusing on pregnant women and child deaths, amid disputes with GOP lawmakers and industry leaders.
Via Benzinga · September 10, 2025
With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.
Via The Motley Fool · September 9, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Via StockStory · September 9, 2025
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 4.8% in the afternoon session after competitors Pfizer and BioNTech announced positive topline results for their updated 2025-2026 COVID-19 vaccine formula. The data from Pfizer and BioNTech showed their vaccine produced a robust immune response, signaling continued strong competition in the COVID-19 vaccine market.
Via StockStory · September 8, 2025
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.
Via Benzinga · September 8, 2025
The company is working on a treatment for a form of epilepsy that tends to be difficult to control.
Via Investor's Business Daily · September 8, 2025
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Via StockStory · September 8, 2025
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.
Via Investor's Business Daily · September 8, 2025
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.
Via The Motley Fool · September 7, 2025
Pfizer's stock is down nearly 60% from its post-pandemic peak, opening up an opportunity for the right long-term investors.
Via The Motley Fool · September 7, 2025
The company might be close to commercializing its most advanced pipeline program.
Via The Motley Fool · September 5, 2025